After the first PI3K inhibitor (alpelisib) was approved by the FDA to treat breast cancer patients with PIK3CA-mutations, people expected precision-based PI3K inhibitors to would be beneficial to PIK3CA-mutated NPC patients in the future (Tsang et al. 2020; Zhang et al. 2020). The gene discussed is PIK3CA; the disease is breast carcinoma.